US Stock MarketDetailed Quotes

VXRT Vaxart

  • 0.860
  • -0.037-4.10%
Close May 21 16:00 ET
  • 0.858
  • -0.002-0.28%
Post 17:38 ET
152.06MMarket Cap-1653P/E (TTM)

About Vaxart Company

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

Company Profile

Company NameVaxart
Listing DateDec 1, 1969
Issue Price8.00
CEOMr. Steven Lo
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address170 Harbor Way,Suite 300
CitySouth San Francisco
CountryUnited States of America
Zip Code94080

Company Executives

  • Name
  • Position
  • Salary
  • Steven Lo
  • Director, President and Chief Executive Officer
  • --
  • Phillip E. Lee
  • Chief Financial Officer and Principal Accounting Officer
  • --
  • Dr. Sean N. Tucker, PhD
  • Senior Vice President and Chief Scientific Officer
  • 1.14M
  • James F. Cummings
  • Chief Medical Officer
  • 1.17M
  • Edward B. Berg
  • Senior Vice President and General Counsel
  • --
  • Dr. Michael J. Finney, PhD
  • Chairman of the Board
  • 109.57K
  • Dr. Elaine J. Heron,PhD
  • Independent Director
  • 89.08K
  • Robert A. Yedid
  • Independent Director
  • 92.26K
  • W. Mark Watson
  • Independent Director
  • 94.76K
  • Dr. David E. Wheadon, M.D.
  • Lead Independent Director
  • 93.72K


Analyst Rating

No Data

Price Target

No Data

Heat List
Latest Price